{"entity":{"id":"nct07827053","kind":"trial","name":"Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of adebrelimab and nALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) in pancreatic cancer, run by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, not yet recruiting.","summary":"Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer is a phase 2, interventional study registered as NCT07827053 by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, with a registry enrolment figure of 36 participants, started 2026-09-01 and due to reach its primary completion in 2029-09-01. Interventions recorded: Adebrelimab (PD-L1 inhibitor); NALIRIFOX; SBRT. Conditions listed: Pancreatic Ductal Adenocarcinoma (PDAC). Primary outcome: surgical conversion rate. Pancreatic eligibility wording from the registry: \"Histologically or cytologically confirmed pancreatic ductal adenocarcinoma\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07827053","url":"https://clinicaltrials.gov/study/NCT07827053"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum","sbrt","topoisomerase-inhibitors"],"targets":[],"drugs":["adebrelimab","nalirifox"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07827053","phase":"2","setting":"Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","enrolled":36,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07827053/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"},{"id":"nalirifox","kind":"drug","name":"NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV)","route":"/drugs/nalirifox/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}